Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin Pharmaceuticals has obtained FDA approval for Suprax (Cefixime) for oral suspension, 500 mg/5mL and anticipates initiating product shipment shortly.
Subscribe to our email newsletter
Suprax oral suspension is indicated for otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea (cervical/urethral) and pharyngitis/tonsillitis.
Lupin Group president Vinita Gupta said, "The new dosage form will add to our growing Suprax franchise and gives health care providers and patients a new formulation to treat the indicted infections."
At present, Suprax is available as 100mg/5ml and 200mg/5ml suspensions, 400mg tablets besides chewable tablets of 100 and 200mg strengths.